Document is current
Any future updates will be listed below
-
Authors
Nakai, Kazuki
Lin, Hancheng
Yamano, Shotaro https://orcid.org/0000-0002-3611-622X
Tanaka, Shinya
Kitamoto, Sho https://orcid.org/0000-0003-3597-6647
Saitoh, Hitoshi
Sakuma, Kenta
Kurauchi, Junpei
Akter, Eilma
Konno, Masamitsu
Ishibashi, Kojiro
Kamata, Ryo https://orcid.org/0000-0001-6970-9657
Ohashi, Akihiro https://orcid.org/0000-0002-4036-9385
Koseki, Jun https://orcid.org/0000-0002-6473-4076
Takahashi, Hirotaka
Yokoyama, Hideshi
Shiraki, Yukihiro https://orcid.org/0000-0003-3666-0556
Enomoto, Atsushi https://orcid.org/0000-0002-9206-6116
Abe, Sohei
Hayakawa, Yoku https://orcid.org/0000-0002-3988-2499
Ushiku, Tetsuo
Mutoh, Michihiro
Fujita, Yasuyuki
Kon, Shunsuke https://orcid.org/0000-0002-2693-6128
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (19217462)
MEXT | Japan Society for the Promotion of Science (20H03166, 21H00441)
- License Information
-
More Information
Article History
Received: 14 December 2022
Accepted: 20 October 2023
First Online: 3 November 2023
Competing interests
: A.O. is currently a part-time employee of Astellas Pharma Inc. through a cross-appointment system and was previously employed by Takeda Pharmaceutical Company, Ltd. A.O. has reported paid consulting or advisory roles for Ono Pharmaceutical Company Ltd., Craif Inc., and GEXVal Inc., which are not relevant to this study. The remaining authors declare no competing interests.
